|
1
|
Hu X, Schwarz JK, Lewis JS Jr, et al: A
microRNA expression signature for cervical cancer prognosis. Cancer
Res. 70:1441–1448. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar
|
|
3
|
Sturgeon CM, Duffy MJ, Hofmann BR, et al:
National Academy of Clinical Biochemistry Laboratory Medicine
Practice Guidelines for use of tumor markers in liver, bladder,
cervical, and gastric cancers. Clin Chem. 56:e1–e48. 2010.
View Article : Google Scholar
|
|
4
|
Hacker NF: Cervical cancer. Practical
Gynecologic Oncology. Berek JS and Hacker NF: 3rd edition.
Lippincott Williams and Wilkins; Philadelphia, PA: pp. 345–405.
2000
|
|
5
|
Neoadjuvant chemotherapy for locally
advanced cervical cancer: a systematic review and meta-analysis of
individual patient data from 21 randomised trials. Eur J Cancer.
39:2470–2486. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lee YY, Choi CH, Sung CO, et al:
Prognostic value of pre-treatment circulating monocyte count in
patients with cervical cancer: comparison with SCC-Ag level.
Gynecol Oncol. 124:92–97. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Huang EY, Wang CJ, Chen HC, et al:
Multivariate analysis of para-aortic lymph node recurrence after
definitive radiotherapy for stage IB-IVA squamous cell carcinoma of
uterine cervix. Int J Radiat Oncol Biol Phys. 72:834–842. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ogino I, Nakayama H, Okamoto N, Kitamura T
and Inoue T: The role of pretreatment squamous cell carcinoma
antigen level in locally advanced squamous cell carcinoma of the
uterine cervix treated by radiotherapy. Int J Gynecol Cancer.
16:1094–1100. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Nakamura K, Okumura Y, Kodama J, Hongo A,
Kanazawa S and Hiramatsu Y: The predictive value of measurement of
SUVmax and SCC-antigen in patients with pretreatment of primary
squamous cell carcinoma of cervix. Gynecol Oncol. 119:81–86. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
van de Lande J, Davelaar EM, von
Mensdorff-Pouilly S, et al: SCC-Ag, lymph node metastases and
sentinel node procedure in early stage squamous cell cervical
cancer. Gynecol Oncol. 112:119–125. 2009.PubMed/NCBI
|
|
11
|
Matsuda H, Mori M, Tsujitani S, Ohno S,
Kuwano H and Sugimachi K: Immunohistochemical evaluation of
squamous cell carcinoma antigen and S-100 protein-positive cells in
human malignant esophageal tissues. Cancer. 65:2261–2265. 1990.
View Article : Google Scholar
|
|
12
|
Krzystek-Korpacka M, Matusiewicz M,
Diakowska D, Grabowski K, Blachut K and Banas T: Upregulation of
VEGF-C secreted by cancer cells and not VEGF-A correlates with
clinical evaluation of lymph node metastasis in esophageal squamous
cell carcinoma (ESCC). Cancer Lett. 249:171–177. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gaarenstroom KN, Bonfrer JM, Korse CM,
Kenter GG and Kenemans P: Value of Cyfra 21-1, TPA, and SCC-Ag in
predicting extracervical disease and prognosis in cervical cancer.
Anticancer Res. 17:2955–2958. 1997.PubMed/NCBI
|
|
14
|
Chen J, Yao D and Wu Z: Diagnostic value
of serum squamous cell carcinoma antigen on lymphatic metastasis in
early-stage cervical cancer: a meta-analysis. Cancer Res Prev
Treat. 39:811–817. 2012.(In Chinese).
|
|
15
|
Enfield KS, Stewart GL, Pikor LA, et al:
MicroRNA gene dosage alterations and drug response in lung cancer.
J Biomed Biotechnol. 2011:4746322011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Medina PP, Nolde M and Slack FJ: OncomiR
addiction in an in vivo model of microRNA-21-induced pre-B-cell
lymphoma. Nature. 467:86–90. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang XW, Heegaard NH and Orum H: MicroRNAs
in liver disease. Gastroenterology. 142:1431–1443. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Liu R, Chen X, Du Y, et al: Serum microRNA
expression profile as a biomarker in the diagnosis and prognosis of
pancreatic cancer. Clin Chem. 58:610–618. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Jurmeister S, Baumann M, Balwierz A, et
al: MicroRNA-200c represses migration and invasion of breast cancer
cells by targeting actin-regulatory proteins FHOD1 and PPM1F. Mol
Cell Biol. 32:633–651. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hennessey PT, Sanford T, Choudhary A, et
al: Serum microRNA biomarkers for detection of non-small cell lung
cancer. PLoS One. 7:e323072012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wu Q, Lu Z, Li H, Lu J, Guo L and Ge Q:
Next-generation sequencing of microRNAs for breast cancer
detection. J Biomed Biotechnol. 2011:5971452011.PubMed/NCBI
|
|
22
|
Santos CF, Kurhanewicz J, Tabatabai ZL, et
al: Metabolic, pathologic, and genetic analysis of prostate
tissues: quantitative evaluation of histopathologic and mRNA
integrity after HR-MAS spectroscopy. NMR Biomed. 23:391–398.
2010.
|
|
23
|
Hsieh CH, Rau CS, Jeng JC, et al: Whole
blood-derived microRNA signatures in mice exposed to
lipopolysaccharides. J Biomed Sci. 19:692012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Cermelli S, Ruggieri A, Marrero JA,
Ioannou GN and Beretta L: Circulating microRNAs in patients with
chronic hepatitis C and non-alcoholic fatty liver disease. PLoS
One. 6:e239372011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hu Z, Chen X, Zhao Y, et al: Serum
microRNA signatures identified in a genome-wide serum microRNA
expression profiling predict survival of non-small-cell lung
cancer. J Clin Oncol. 28:1721–1726. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wulfken LM, Moritz R, Ohlmann C, et al:
MicroRNAs in renal cell carcinoma: diagnostic implications of serum
miR-1233 levels. PLoS One. 6:e257872011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Iorio MV, Ferracin M, Liu CG, et al:
MicroRNA gene expression deregulation in human breast cancer.
Cancer Res. 65:7065–7070. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jamieson NB, Morran DC, Morton JP, et al:
MicroRNA molecular profiles associated with diagnosis,
clinicopathologic criteria, and overall survival in patients with
resectable pancreatic ductal adenocarcinoma. Clin Cancer Res.
18:534–545. 2012. View Article : Google Scholar
|
|
29
|
Bihrer V, Waidmann O, Friedrich-Rust M, et
al: Serum microRNA-21 as marker for necroinflammation in hepatitis
C patients with and without hepatocellular carcinoma. PLoS One.
6:e269712011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Schwarzenbach H, Milde-Langosch K,
Steinbach B, Muller V and Pantel K: Diagnostic potential of
PTEN-targeting miR-214 in the blood of breast cancer patients.
Breast Cancer Res Treat. 134:933–941. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Roth C, Kasimir-Bauer S, Pantel K and
Schwarzenbach H: Screening for circulating nucleic acids and
caspase activity in the peripheral blood as potential diagnostic
tools in lung cancer. Mol Oncol. 5:281–291. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Li C, Li JF, Cai Q, et al: MiRNA-199a-3p
in plasma as a potential diagnostic biomarker for gastric cancer.
Ann Surg Oncol. Sep 7–2012.(Epub ahead of print).
|
|
33
|
Yu S, Liu Y, Wang J, et al: Circulating
microRNA profiles as potential biomarkers for diagnosis of
papillary thyroid carcinoma. J Clin Endocrinol Metab. 97:2084–2092.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Sakuragi N: Up-to-date management of lymph
node metastasis and the role of tailored lymphadenectomy in
cervical cancer. Int J Clin Oncol. 12:165–175. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Juang CM, Wang PH, Yen MS, Lai CR, Ng HT
and Yuan CC: Application of tumor markers CEA, TPA, and SCC-Ag in
patients with low-risk FIGO stage IB and IIA squamous cell
carcinoma of the uterine cervix. Gynecol Oncol. 76:103–106. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Gaarenstroom KN, Kenter GG, Bonfrer JM, et
al: Can initial serum cyfra 21-1, SCC antigen, and TPA levels in
squamous cell cervical cancer predict lymph node metastases or
prognosis? Gynecol Oncol. 77:164–170. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Tian RQ, Wang XH, Hou LJ, et al:
MicroRNA-372 is down-regulated and targets cyclin-dependent kinase
2 (CDK2) and cyclin A1 in human cervical cancer, which may
contribute to tumorigenesis. J Biol Chem. 286:25556–25563. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Au Yeung CL, Tsang TY, Yau PL and Kwok TT:
Human papillomavirus type 16 E6 induces cervical cancer cell
migration through the p53/microRNA-23b/urokinase-type plasminogen
activator pathway. Oncogene. 30:2401–2410. 2011.PubMed/NCBI
|
|
39
|
Deftereos G, Corrie SR, Feng Q, et al:
Expression of mir-21 and mir-143 in cervical specimens ranging from
histologically normal through to invasive cervical cancer. PLoS
One. 6:e284232011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Pang RT, Leung CO, Ye TM, et al:
MicroRNA-34a suppresses invasion through downregulation of Notch1
and Jagged1 in cervical carcinoma and choriocarcinoma cells.
Carcinogenesis. 31:1037–1044. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Kang HW, Wang F, Wei Q, et al: miR-20a
promotes migration and invasion by regulating TNKS2 in human
cervical cancer cells. FEBS Lett. 586:897–904. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Zhang Y, Liao JM, Zeng SX and Lu H: p53
downregulates Down syndrome-associated DYRK1A through miR-1246.
EMBO Rep. 12:811–817. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Liao JM, Zhou X, Zhang Y and Lu H:
MiR-1246: a new link of the p53 family with cancer and Down
syndrome. Cell Cycle. 11:2624–2630. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Baek KH, Zaslavsky A, Lynch RC, et al:
Down’s syndrome suppression of tumour growth and the role of the
calcineurin inhibitor DSCR1. Nature. 459:1126–1130. 2009.
|
|
45
|
Pigati L, Yaddanapudi SC, Iyengar R, et
al: Selective release of microRNA species from normal and malignant
mammary epithelial cells. PLoS One. 5:e135152010. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Baraniskin A, Nopel-Dunnebacke S, Ahrens
M, et al: Circulating U2 small nuclear RNA fragments as a novel
diagnostic biomarker for pancreatic and colorectal adenocarcinoma.
Int J Cancer. 132:E48–E57. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Matsubara H, Takeuchi T, Nishikawa E, et
al: Apoptosis induction by antisense oligonucleotides against
miR-17-5p and miR-20a in lung cancers overexpressing miR-17-92.
Oncogene. 26:6099–6105. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Huang G, Nishimoto K, Zhou Z, Hughes D and
Kleinerman ES: miR-20a encoded by the miR-17-92 cluster increases
the metastatic potential of osteosarcoma cells by regulating Fas
expression. Cancer Res. 72:908–916. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Fan X, Liu Y, Jiang J, et al: miR-20a
promotes proliferation and invasion by targeting APP in human
ovarian cancer cells. Acta Biochim Biophys Sin (Shanghai).
42:318–324. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Chai H, Liu M, Tian R, Li X and Tang H:
miR-20a targets BNIP2 and contributes chemotherapeutic resistance
in colorectal adenocarcinoma SW480 and SW620 cell lines. Acta
Biochim Biophys Sin (Shanghai). 43:217–225. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Zhang M, Liu Q, Mi S, et al: Both
miR-17-5p and miR-20a alleviate suppressive potential of
myeloid-derived suppressor cells by modulating STAT3 expression. J
Immunol. 186:4716–4724. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Li X, Pan JH, Song B, et al: Suppression
of CX43 expression by miR-20a in the progression of human prostate
cancer. Cancer Biol Ther. 13:890–898. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Wang W, Feng L, Zhang H, et al:
Preeclampsia up-regulates angiogenesis-associated microRNA (i.e.,
miR-17, -20a, and -20b) that target ephrin-B2 and EPHB4 in human
placenta. J Clin Endocrinol Metab. 97:E1051–E1059. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Poliseno L, Pitto L, Simili M, et al: The
proto-oncogene LRF is under post-transcriptional control of
MiR-20a: implications for senescence. PLoS One. 3:e25422008.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Wu H, Wang F, Hu S, et al: MiR-20a and
miR-106b negatively regulate autophagy induced by leucine
deprivation via suppression of ULK1 expression in C2C12 myoblasts.
Cell Signal. 24:2179–2186. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Elkayam E, Kuhn CD, Tocilj A, et al: The
structure of human argonaute-2 in complex with miR-20a. Cell.
150:100–110. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Stark MS, Tyagi S, Nancarrow DJ, et al:
Characterization of the melanoma miRNAome by deep sequencing. PLoS
One. 5:e96852010. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Persson H, Kvist A, Rego N, et al:
Identification of new microRNAs in paired normal and tumor breast
tissue suggests a dual role for the ERBB2/Her2 gene. Cancer Res.
71:78–86. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Jima DD, Zhang J, Jacobs C, et al: Deep
sequencing of the small RNA transcriptome of normal and malignant
human B cells identifies hundreds of novel microRNAs. Blood.
116:e118–e127. 2010. View Article : Google Scholar : PubMed/NCBI
|
